Italia Markets closed

Hercules Capital, Inc. (0J4M.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
12,77-0,39 (-2,94%)
Alla chiusura: 04:01PM BST
Schermo intero
Chiusura precedente13,16
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno12,71 - 12,95
Intervallo di 52 settimane12,71 - 12,95
Media VolumeN/D
Beta (5 anni mensile)1,31
Rapporto PE (ttm)4,56
EPS (ttm)2,80
Prossima data utili27 apr 2022 - 02 mag 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Alladapt Announces Loan Agreement with Hercules Capital

    Access to term loan of up to $50 million supports clinical development of ADP101 through initiation of Phase 3 trial and completion of Alladapt’s manufacturing facility Recent oversubscribed $119 million institutional financing in addition to this non-dilutive financing extends cash runway into 2024 MENLO PARK, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediate

  • GlobeNewswire

    atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update

    - Added an anticipated additional year of runway into 2025 through securing non-dilutive debt facility from Hercules combined with execution of cost optimizations by prioritizing atai’s development programs with anticipated meaningful near-term clinical value inflections- Key achieved R&D milestones include completion of the clinical phase of the Drug-Drug-Interaction (DDI) study of PCN-101, database lock for the GRX-917 Phase 1 trial, completion of SAD portion of ongoing KUR-101 Phase 1 trial,

  • GlobeNewswire

    atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital

    - Non-dilutive financing facility, plus $312M existing cash on hand as of June 30, 2022, gives atai access to up to $487M to continue developing next generation mental health treatments - Flexible draw availability provides optionality to optimize liquidity and capital structure moving forward NEW YORK and BERLIN, Aug. 15, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorde